Peptide ·Emerging evidence ·Reviewed May 2026
Thymosin Beta-4 is an endogenous 43-amino-acid peptide involved in actin regulation, cell migration, angiogenesis, and tissue repair. It is not FDA-approved as a systemic injectable drug; ophthalmic thymosin beta-4 formulations have been studied but remain investigational in the United States. Evidence is strongest for topical or ophthalmic research contexts, not wellness injection protocols.
The bottom line
Evidence rating emerging. Most-documented uses: studied for ocular surface healing, supports cell migration in repair models, investigational wound-healing biology. 3 sources indexed (2010–2022), with 3 interaction records on file.
Core mechanism
Thymosin beta-4 binds G-actin and helps regulate actin polymerization, supporting epithelial and endothelial cell migration during repair. It also influences inflammatory signaling, apoptosis, angiogenesis, and extracellular matrix remodeling in preclinical models. These effects do not establish that unregulated TB-500 or systemic peptide products are safe or effective for injury recovery.1,2
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.2
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Investigational Ophthalmic Solution.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Dose: Protocol-specific ophthalmic dosing3
Timing: Per study protocol
Studied for dry eye and neurotrophic keratopathy but not an approved US drug.
Dose: No FDA-approved dose3
Timing: Not applicable
Preclinical repair biology does not justify unsupervised injection.
Dose: No approved dose
Timing: Not applicable
Long-term systemic safety, angiogenesis risk, and efficacy are not established.
Where this appears in the symptom-to-supplement map, ranked by relevance.
Ophthalmic thymosin beta-4 has been studied for ocular surface signs.1,2
Use approved dry-eye therapies first.
Repair biology involves cell migration and angiogenesis, but systemic self-use is unproven.3
Seek wound care for nonhealing wounds.
Tendon repair claims are mostly extrapolated from repair models.3
Rule out tear or overuse injury.
Fish oil may modestly increase bleeding or bruising tendency, which matters around wounds, procedures, or injections.
Recommendation: Pause nonessential bleeding-risk supplements before procedures according to clinician guidance.
Ginkgo may increase bleeding risk and can complicate wound or procedure recovery.
Recommendation: Avoid combining around surgery or open wounds unless a clinician approves.
High-dose vitamin E may increase bruising risk around injections or procedures.
Recommendation: Use conservative vitamin E doses and disclose all supplements before procedures.
Numbered references. Citations throughout the page link here.
Primary endpoints were mixed
No dose-limiting toxicity was reported
Angiogenic and anti-inflammatory mechanisms were reviewed
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
